Based on the Gilead Sciences Inc stock forecast from 21 analysts, the average analyst target price for Gilead Sciences Inc is USD 90.03 over the next 12 months. Gilead Sciences Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Gilead Sciences Inc is Neutral, which is based on 7 positive signals and 6 negative signals. At the last closing, Gilead Sciences Inc’s stock price was USD 92.57. Gilead Sciences Inc’s stock price has changed by +1.20% over the past week, +3.13% over the past month and +17.28% over the last year.
No recent analyst target price found for Gilead Sciences Inc
No recent average analyst rating found for Gilead Sciences Inc
Company Overview Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California. Read Less
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Strib...Read More
Frequently Asked Questions About Gilead Sciences Inc (GILD) Stock
Based on ratings from 21 analysts Gilead Sciences Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Neutral. The stock has 19 buy, sell and 18 hold ratings.
GILD stock's dividend yield is 3.33%.
Our analysis grades GILD stock's dividend yield at C. This means that GILD stock's dividend yield is above 75% of the stocks in the Drug Manufacturers - General sector in the NSD exchange.
Based on this GILD may be a average dividend stock for its sector.
Based on targets from 21 analysts, the average taret price for GILD is USD 90.03 over the next 12 months. The maximum analyst target price is USD 125 while the minimum anlayst target price is USD 70.
GILD stock's Price/Earning ratio is 1,020.61.
Our analysis grades GILD stock's Price / Earning ratio at F. This means that GILD stock's Price/Earning ratio is above 86% of the stocks in the Drug Manufacturers - General sector in the NSD exchange.
Based on this GILD may be a overvalued for its sector.
The last closing price of GILD's stock was USD 92.57.
The most recent market capitalization for GILD is USD 115.13B.
Based on targets from 21 analysts, the average taret price for GILD is projected at USD 90.03 over the next 12 months.
This means that GILD's stock price may go down by -2.75% over the next 12 months.
We can't find any ETFs which contains Gilead Sciences Inc's stock.
As per our most recent records Gilead Sciences Inc has 18,000 Employees.
Gilead Sciences Inc's registered address is 333 Lakeside Drive, Foster City, CA, United States, 94404.
You can get more information about it from Gilead Sciences Inc's website at https://www.gilead.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior Dividend Growth
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Gilead Sciences Inc (GILD) Stock
Based on ratings from 21 analysts Gilead Sciences Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Neutral. The stock has 19 buy, sell and 18 hold ratings.
GILD stock's dividend yield is 3.33%.
Our analysis grades GILD stock's dividend yield at C. This means that GILD stock's dividend yield is above 75% of the stocks in the Drug Manufacturers - General sector in the NSD exchange.
Based on this GILD may be a average dividend stock for its sector.
Based on targets from 21 analysts, the average taret price for GILD is USD 90.03 over the next 12 months. The maximum analyst target price is USD 125 while the minimum anlayst target price is USD 70.
GILD stock's Price/Earning ratio is 1,020.61.
Our analysis grades GILD stock's Price / Earning ratio at F. This means that GILD stock's Price/Earning ratio is above 86% of the stocks in the Drug Manufacturers - General sector in the NSD exchange.
Based on this GILD may be a overvalued for its sector.
The last closing price of GILD's stock was USD 92.57.
The most recent market capitalization for GILD is USD 115.13B.
Based on targets from 21 analysts, the average taret price for GILD is projected at USD 90.03 over the next 12 months.
This means that GILD's stock price may go down by -2.75% over the next 12 months.
We can't find any ETFs which contains Gilead Sciences Inc's stock.
As per our most recent records Gilead Sciences Inc has 18,000 Employees.
Gilead Sciences Inc's registered address is 333 Lakeside Drive, Foster City, CA, United States, 94404.
You can get more information about it from Gilead Sciences Inc's website at https://www.gilead.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for GILD !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
